NYSE
43.37USD
-0.55 (-1.24%)
We have scored 85 news catalysts on Boston Scientific Corporation (BSX) over the past 12 months. The biggest single-day move next to one of them came Sep 14, 2026, when BSX closed +4.8%: “Advanced Diamond Materials and Technology Market Set for Strong Growth Through 2036, Driven by Semiconductor, Quantum Computing and Thermal Management Demand”. Coverage across the window leans negative (average ticker sentiment −0.37). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
64.7B
P/E
—
EPS
—
Beta
0.57
52W range
42.2-105.65
Day range
42.95–43.66
Open
43.47
Prev close
43.91
Volume
18.4M
Avg volume
20.7M
Dividend
0.00
IPO
1992-05-19
Analysts publish price targets on BSX, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
30 analyst price targets from $50 to $89
as of 2026-09-10
The market is 31% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Boston Scientific Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Boston Scientific Corporation, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for BSX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
The price sits at the very bottom of the published model range, 31% below the median target, meaning the market has fully absorbed the recent guidance cuts and operational setbacks and refuses to pay for any recovery.
What the disagreement turns on
Can the company stabilize its U.S. WATCHMAN and electrophysiology segments and restore shipments after the cyberattack, and the available data can measure the revenue impact but cannot measure the operational disruption directly.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
